Aspire Pharma Tropicamide Recall: MHRA Issues Class 3 for Incorrect Expiry

• Aspire Pharma has issued a Class 3 Medicines Recall for specific batches of Tropicamide 1% Eye Drops.
• The recall is due to an incorrect expiry date printed on the product packaging.
• The correct expiry date for the affected batches is October 31, 2026.
• Pharmacies and wholesalers must immediately stop supplying and quarantine all remaining stock.
• Patients should continue using the eye drops but contact their prescriber for a replacement prescription.

This Aspire Pharma incorrect expiry date recall serves as a significant reminder for all stakeholders in the healthcare sector about the continuous need for robust quality control and adherence to regulatory guidelines.

Aspire Pharma Ltd has initiated a Class 3 Medicines Recall for specific batches of its Tropicamide 1% Eye Drops, which are supplied in single-dose containers of 0.5ml x 20. The recall, identified by reference EL(26)A/47, stems from an error in the product's packaging where an incorrect expiry date was printed. For the affected batches, the accurate expiry date should be October 31, 2026. This action highlights the critical importance of precise labeling within the pharmaceutical supply chain.

As a direct consequence of this recall, all pharmacies and wholesalers are instructed to immediately cease the supply of the identified batches. Furthermore, any remaining stock of these particular batches must be quarantined without delay. The company has directed that all affected products be returned to the supplier following their established return procedures. This measure is being undertaken as a precautionary step to ensure product integrity and adherence to regulatory standards.

The Medicines and Healthcare products Regulatory Agency (MHRA) oversees this Class 3 Medicines Recall, which is specifically targeted at the pharmacy and wholesaler level. This classification indicates that while the defect is not considered life-threatening, it still necessitates prompt action within the distribution network. The core issue revolves around an incorrect expiry date, a fundamental piece of information for pharmaceutical products, underscoring the stringent requirements for UK pharmaceutical recall compliance.

Despite the labeling discrepancy, no adverse incidents directly attributable to this defect have been reported to date. The active ingredient in the recalled product is tropicamide, with a SNOMED code of 45542111000001107. The MHRA's involvement ensures that the recall process is managed effectively, maintaining public health standards and addressing potential risks before they escalate.

For patients currently using the affected Tropicamide 1% Eye Drops, no immediate action is required regarding their medication use. Patients are advised to continue using the eye drops as prescribed. However, they should contact their prescriber to arrange for a replacement prescription, ensuring they receive correctly labeled product in due course. This approach prioritizes uninterrupted treatment while addressing the labeling error.

This Aspire Pharma incorrect expiry date recall serves as a significant reminder for all stakeholders in the healthcare sector about the continuous need for robust quality control and adherence to regulatory guidelines. Any patients experiencing adverse reactions or having questions about their medication should seek medical attention and are encouraged to report suspected adverse reactions through the MHRA Yellow Card scheme. For specific inquiries, Aspire Pharma has provided contact details: medinfo@aspirepharma.com or 0044 1730 231148 for medical information, and customerservices@aspirepharma.com or 0044 1730 231148 for stock control inquiries.

For compliance officers and legal counsel in pharmaceutical distribution, pharmacies, and healthcare providers, this recall necessitates immediate action to cease supply and quarantine affected batches of Aspire Pharma's Tropicamide 1% Eye Drops due to incorrect expiry date labelling. It underscores the critical need for robust supply chain compliance and adherence to MHRA recall procedures to mitigate regulatory risks and ensure patient safety.

Source: Original reporting via MHRA recall notice.